Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.

Hsieh, Yi-Chung

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. [electronic resource] - PloS one 2018 - e0202777 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1932-6203

10.1371/journal.pone.0202777 doi


2-Naphthylamine
Aged
Aged, 80 and over
Anilides--administration & dosage
Antiviral Agents--administration & dosage
Carbamates--administration & dosage
Cohort Studies
Cyclopropanes
Drug Therapy, Combination
Female
Genotype
Hepacivirus--genetics
Hepatitis C, Chronic--drug therapy
Humans
Hyperbilirubinemia--chemically induced
Lactams, Macrocyclic
Liver Cirrhosis--drug therapy
Macrocyclic Compounds--administration & dosage
Male
Middle Aged
Proline--analogs & derivatives
Prospective Studies
Risk Factors
Ritonavir--administration & dosage
Sulfonamides--administration & dosage
Sustained Virologic Response
Treatment Outcome
Uracil--administration & dosage
Valine